Ironwood Pharmaceuticals (IRWD)
(Delayed Data from NSDQ)
$4.26 USD
+0.24 (5.97%)
Updated Oct 2, 2024 04:00 PM ET
After-Market: $4.26 0.00 (0.00%) 7:58 PM ET
5-Strong Sell of 5 5
C Value C Growth D Momentum D VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$4.26 USD
+0.24 (5.97%)
Updated Oct 2, 2024 04:00 PM ET
After-Market: $4.26 0.00 (0.00%) 7:58 PM ET
5-Strong Sell of 5 5
C Value C Growth D Momentum D VGM
Zacks News
Ironwood Pharmaceuticals (IRWD) Looks Good: Stock Adds 7.6% in Session
by Zacks Equity Research
Ironwood Pharmaceuticals (IRWD) saw a big move last session, as its shares jumped nearly 8% on the day, amid huge volumes.
Ironwood to Halt MD-7246 Development After Study Failure
by Zacks Equity Research
Ironwood's (IRWD) pipeline candidate, MD-7246 fails to meet primary endpoint in a phase II study evaluating it in patients with irritable bowel syndrome with diarrhea.
Ironwood (IRWD) Misses Q1 Earnings and Revenue Estimates
by Zacks Equity Research
Ironwood (IRWD) witnesses strong demand for Linzess in the first quarter. COVID-19 impacts enrollment in clinical studies.
Ironwood Pharmaceuticals (IRWD) Misses Q1 Earnings and Revenue Estimates
by Zacks Equity Research
Ironwood (IRWD) delivered earnings and revenue surprises of -63.64% and -7.90%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?
Ironwood Pharmaceuticals (IRWD) Reports Next Week: Wall Street Expects Earnings Growth
by Zacks Equity Research
Ironwood (IRWD) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Can Ironwood (IRWD) Keep the Earnings Surprise Streak Alive?
by Zacks Equity Research
Ironwood (IRWD) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Ironwood (IRWD) Down 22.1% Since Last Earnings Report: Can It Rebound?
by Zacks Equity Research
Ironwood (IRWD) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Ironwood (IRWD) Surpasses Q4 Earnings and Sales Estimates
by Zacks Equity Research
Ironwood (IRWD) witnesses strong demand for Linzess in the fourth quarter as well. Stock up.
Ironwood (IRWD) Beats Earnings & Revenues Estimates in Q4
by Zacks Equity Research
Ironwood Pharmaceuticals (IRWD) reports higher-than-expected earnings and revenues in the fourth quarter.
What's in Store for Ironwood (IRWD) This Earnings Season?
by Zacks Equity Research
Ironwood Pharmaceuticals' (IRWD) Linzess is likely to have driven total revenues in the fourth quarter.
Ironwood Pharmaceuticals (IRWD) Earnings Expected to Grow: Should You Buy?
by Zacks Equity Research
Ironwood (IRWD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
5 Reasons Why Ironwood Stock Should Be in Your Portfolio
by Zacks Equity Research
We provide five reasons which makes Ironwood (IRWD) a good investment option in 2020.
MEI Pharma (MEIP) Catches Eye: Stock Jumps 8.1%
by Zacks Equity Research
MEI Pharma (MEIP) saw a big move last session, as its shares jumped more than 8% on the day, amid huge volumes.
Are You Looking for a Top Momentum Pick? Why Ironwood Pharmaceuticals (IRWD) is a Great Choice
by Zacks Equity Research
Does Ironwood Pharmaceuticals (IRWD) have what it takes to be a top stock pick for momentum investors? Let's find out.
Marinus Pharmaceuticals (MRNS) Catches Eye: Stock Jumps 7.7%
by Zacks Equity Research
Marinus Pharmaceuticals (MRNS) shares rose nearly 8% in the last trading session, amid huge volumes.
Is Ironwood Pharmaceuticals (IRWD) Outperforming Other Medical Stocks This Year?
by Zacks Equity Research
Is (IRWD) Outperforming Other Medical Stocks This Year?
Moving Average Crossover Alert: Ironwood Pharmaceuticals
by Zacks Equity Research
Ironwood Pharmaceuticals, Inc. (IRWD) is looking like an interesting pick from a technical perspective, as the company is seeing favorable trends on the moving average crossover front.
Pacira's Late-Stage Study on Exparel Label Expansion Positive
by Zacks Equity Research
Pacira (PCRX) releases positive top-line data from its phase III PLAY study evaluating the pharmacokinetics and safety of Exparel in two patient groups.
Assertio to Divest Shingles Pain Drug to Alvogen for $127.5M
by Zacks Equity Research
Assertio (ASRT) inks a deal to sell Gralise to Alvogen for a total value of $127.5 million.
Turning Point (TPTX) Catches Eye: Stock Jumps 6.1%
by Zacks Equity Research
Turning Point (TPTX) saw a big move last session, as its shares jumped more than 6% on the day, amid huge volumes.
Sage Therapeutics (SAGE) in Focus: Stock Moves 7.1% Higher
by Zacks Equity Research
Sage Therapeutics (SAGE) shares rose more than 7% in the last trading session, amid huge volumes.
Top Ranked Momentum Stocks to Buy for December 3rd
by Zacks Equity Research
Here are four stocks with buy rank and strong momentum characteristics for investors to consider today, December 3rd
Catalyst Focuses on Firdapse Label Expansion Amid Competition
by Zacks Equity Research
Catalyst (CPRX) focuses on the development of Firdapse for additional indications.
The Zacks Analyst Blog Highlights: DexCom, Forterra, NeoPhotonics, Ironwood and Cardtronics
by Zacks Equity Research
The Zacks Analyst Blog Highlights: DexCom, Forterra, NeoPhotonics, Ironwood and Cardtronics
5 Best-Performing, Top-Ranked Growth Stocks of November
by Nalak Das
Wall Street's impressive bull run is likely to continue in the near term. At this stage, it will be prudent to invest in growth stocks with a favorable Zacks Rank.